Socrates Herrera

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/647845/publications.pdf

Version: 2024-02-01

19	812	516710 16	794594 19
papers	citations	h-index	g-index

22	22	22	810
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Current status ofPlasmodium vivaxvaccine. Hum Vaccin, 2010, 6, 124-132.	2.4	86
2	SAFETY AND ELICITATION OF HUMORAL AND CELLULAR RESPONSES IN COLOMBIAN MALARIA-NAIVE VOLUNTEERS BY A PLASMODIUM VIVAX CIRCUMSPOROZOITE PROTEINâ€“DERIVED SYNTHETIC VACCINE. American Journal of Tropical Medicine and Hygiene, 2005, 73, 3-9.	1.4	74
3	ANTIGENICITY, IMMUNOGENICITY, AND PROTECTIVE EFFICACY OF PLASMODIUM VIVAX MSP1 PV200L: A POTENTIAL MALARIA VACCINE SUBUNIT. American Journal of Tropical Medicine and Hygiene, 2005, 73, 16-24.	1.4	67
4	Phase I Safety and Immunogenicity Trial of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51. American Journal of Tropical Medicine and Hygiene, 2011, 84, 12-20.	1.4	65
5	Consistent Safety and Infectivity in Sporozoite Challenge Model of Plasmodium vivax in Malaria-Naive Human Volunteers. American Journal of Tropical Medicine and Hygiene, 2011, 84, 4-11.	1.4	60
6	Clinical profile of Plasmodium falciparum and Plasmodium vivax infections in low and unstable malaria transmission settings of Colombia. Malaria Journal, 2015, 14, 154.	2.3	60
7	Successful Sporozoite Challenge Model in Human Volunteers with Plasmodium vivax Strain Derived from Human Donors. American Journal of Tropical Medicine and Hygiene, 2009, 81, 740-746.	1.4	55
8	Plasmodium vivax Sporozoite Challenge in Malaria-NaÃ¯ve and Semi-Immune Colombian Volunteers. PLoS ONE, 2014, 9, e99754.	2.5	52
9	Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial. PLoS Neglected Tropical Diseases, 2016, 10, e0005070.	3.0	50
10	Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein. International Journal for Parasitology, 2004, 34, 1535-1546.	3.1	49
11	High prevalence of sub-microscopic infections in Colombia. Malaria Journal, 2015, 14, 201.	2.3	42
12	Transcription Profiling of Malaria-NaÃ¯ve and Semi-immune Colombian Volunteers in a Plasmodium vivax Sporozoite Challenge. PLoS Neglected Tropical Diseases, 2015, 9, e0003978.	3.0	32
13	Clinical and epidemiological aspects of complicated malaria in Colombia, 2007â€“2013. Malaria Journal, 2016, 15, 269.	2.3	29
14	Complicated malaria in children and adults from three settings of the Colombian Pacific Coast: A prospective study. PLoS ONE, 2017, 12, e0185435.	2.5	24
15	Antibody-Mediated and Cellular Immune Responses Induced in Naive Volunteers by Vaccination with Long Synthetic Peptides Derived from the Plasmodium vivax Circumsporozoite Protein. American Journal of Tropical Medicine and Hygiene, 2011, 84, 35-42.	1.4	21
16	Preclinical Vaccine Study of Plasmodium vivax Circumsporozoite Protein Derived-Synthetic Polypeptides Formulated in Montanide ISA 720 and Montanide ISA 51 Adjuvants. American Journal of Tropical Medicine and Hygiene, 2011, 84, 21-27.	1.4	21
17	Malaria Vaccine Development Using Synthetic Peptides as a Technical Platform. Advances in Immunology, 2012, 114, 107-149.	2.2	14
18	Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine. Nature Communications, 2022, 13, 1603.	12.8	9

#	Article	IF	Citations
19	Individualized Transcriptional Resolution of Complicated Malaria in a Colombian Study. Journal of Personalized Medicine, 2018, 8, 29.	2.5	2